Alexander Scheiter
Overview
Explore the profile of Alexander Scheiter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Scheiter A, Hierl F, Winkel I, Keil F, Klier-Richter M, Coulouarn C, et al.
J Pers Med
. 2022 Aug;
12(8).
PMID: 36013219
Cholangiocarcinoma (CCA) features a dismal prognosis with limited treatment options. Genomic studies have unveiled several promising targets in this disease, including fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase...
12.
Strotzer Q, Winther H, Utpatel K, Scheiter A, Fellner C, Doppler M, et al.
Diagnostics (Basel)
. 2022 Aug;
12(8).
PMID: 36010288
We aimed to evaluate whether U-shaped convolutional neuronal networks can be used to segment liver parenchyma and indicate the degree of liver fibrosis/cirrhosis at the voxel level using contrast-enhanced magnetic...
13.
Nooijen L, Banales J, de Boer M, Braconi C, Folseraas T, Forner A, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35625993
Background: Lymph node metastasis and positive resection margins have been reported to be major determinants of overall survival (OS) and poor recurrence-free survival (RFS) for patients who underwent resection for...
14.
Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klumpen H, et al.
J Hepatol
. 2022 Feb;
76(5):1109-1121.
PMID: 35167909
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic...
15.
Neumann B, Angstwurm K, Linker R, Knoll G, Eidenschink L, Rubbenstroth D, et al.
Cell Rep Med
. 2022 Feb;
3(1):100499.
PMID: 35106511
Borna disease virus 1 (BoDV-1) causes rare but often fatal encephalitis in humans. Late diagnosis prohibits an experimental therapeutic approach. Here, we report a recent case of fatal BoDV-1 infection...
16.
Haimerl M, Utpatel K, Gotz A, Zeman F, Fellner C, Nickel D, et al.
Sci Rep
. 2021 Nov;
11(1):22991.
PMID: 34837039
This study aimed to assess the degree of differentiation of hepatocellular carcinoma (HCC) using Gd-EOB-DTPA-assisted magnetic resonance imaging (MRI) with T1 relaxometry. Thirty-three solitary HCC lesions were included in this...
17.
Scheiter A, Evert K, Reibenspies L, Cigliano A, Annweiler K, Muller K, et al.
Mol Oncol
. 2021 Nov;
16(5):1091-1118.
PMID: 34748271
Aberrant activation of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR and Ras/mitogen-activated protein kinase (MAPK) pathways is a hallmark of hepatocarcinogenesis. In a subset of hepatocellular carcinomas (HCCs), PI3K/AKT/mTOR signaling dysregulation depends on...
18.
Gerthofer V, Scheiter A, Luke F, Keil F, Utpatel K, Pohmerer L, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34568722
No abstract available.
19.
Jesinghaus M, Schmitt M, Lang C, Reiser M, Scheiter A, Konukiewitz B, et al.
Am J Surg Pathol
. 2021 Jun;
45(7):969-978.
PMID: 34105518
The 2019 World Health Organization (WHO) classification of colorectal carcinoma (CRC) profoundly reclassified CRC subtypes and introduces tumor budding as a second major grading criterion, while condensing conventional grade into...
20.
Scheiter A, Keil F, Luke F, Grosse J, Verloh N, Opitz S, et al.
Curr Oncol
. 2021 Apr;
28(2):1161-1169.
PMID: 33800328
Fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a new therapeutic target for cholangiocarcinoma in clinical practice following the United States Food and Drug Administration (FDA) approval of...